Moreover, there are a variety of targets that inhibit NF-κB signaling to negatively regulate NLRP3 inflammasome, such as Loganin [242], Dapagliflozin [243], Hederasaponin C [244], Artesunate [245], Syringaresinol [246], all of which have been studied in preclinical models of ALI/ARDS. This evidence concerns the gene NLRP3 and acute respiratory distress syndrome.